Enhanced Genomics has announced the appointment of Dr Katerina Leftheris to its Board of Directors.
Leftheris brings more than three decades of senior scientific experience across the pharmaceutical and biotechnology industries to her new role. She was previously Chief Scientific Officer at Vilya. Other roles include Associate Director Chemistry at Bristol Myers Squibb, Senior Director Chemistry at Celgene and Vice President Discovery Chemistry at Pliant Therapeutics.
Leftheris sits on the Board of Directors and Scientific Advisory Boards at various biotechnology companies, with the American Chemical Society recently electing her 2026 Vice Chair for the Medicinal Chemistry (MEDI) Division and member of the Committee on Science.
Leftheris’ appointment will build on the company’s internal therapeutics pipeline, which uses its 3D multi-omics platform to identify genetically validated drug targets for various common diseases and potentially speed up drug discovery.
Dietrich A Stephan, executive chair of Enhanced, said: “[Leftheris’s] expertise in therapeutics discovery and clinical drug development will be an invaluable asset as we progress our plans to drive the next era of precision therapeutics development.”
Leftheris added: “Building on decades of genomics research, Enhanced’s 3D multi-omics platform has the potential to define causal biology, enabling the identification of high-confidence, first-in-class therapeutic targets, to drive the development of truly disease-modifying therapies.”